Crossmark

Response to letter “re: Surgery of the primary tumor in patients with de novo metastatic breast cancer: A nationwide population–based retrospective cohort study in Belgium and the National Cancer Database (NCDB)”

Crossref DOI link: https://doi.org/10.1007/s10549-024-07498-1

Published Online: 2024-10-01

Published Print: 2025-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Martins-Branco, Diogo https://orcid.org/0000-0002-7214-4818
Brandão, Mariana https://orcid.org/0000-0002-1653-3544
de Azambuja, Evandro https://orcid.org/0000-0001-9501-4509
License Information

Text and Data Mining valid from 2024-10-01

Version of Record valid from 2024-10-01
More Information

Article History

Received: 9 September 2024

Accepted: 20 September 2024

First Online: 1 October 2024

Declarations

:

: DMB reports full time employment at European Society for Medical Oncology since September 1, 2023; speaker’s engagement from Daiichi Sankyo/AstraZeneca; participation as medical research fellow in research studies institutionally funded by Eli Lilly, Novartis, and F. Hoffmann-La Roche Ltd to Institut Jules Bordet; non-financial interest as member of the board of directors for Associaҫão de Investigaҫão e Cuidados de Suporte em Oncologia (all outside the submitted work). MB declares travel grant from Roche, Takeda, Merus, AstraZeneca and Sanofi; speaker honoraria from Roche, Takeda, BMS, AstraZeneca and Janssen; advisory board from Sanofi, Pfizer, AstraZeneca, Daiichi Sankyo (all outside the submitted work). EdA reports honoraria and/or advisory board from Roche/GNE, Novartis, SeaGen, Zodiac, Libbs; Pierre Fabre, Lilly, Astra-Zeneca, MSD, and Gilead; travel grants from Roche/GNE and Astra-Zeneca; and institutional research grant from Roche/GNE, Astra-Zeneca, GSK/Novartis and Servier (all outside the submitted work).

Document is current

Any future updates will be listed below